Post by iamaverb on Oct 3, 2018 18:39:48 GMT
I bought 500 shares at $5.80 back in Nov. 2016 just to keep it on my radar along with another Alzheimer stock AVXL. I bought an additional 10K shares at $0.94 back in April of this year when it fell below a dollar and when they said they would announce "Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease" in order to average down. It's called risky business, but whoever makes a breakthrough in Alzheimer research will prove to be a big winner. In the first hour of trading this morning the share price is up another 157% to $5.08, with 56 million shares trading hands, and is up 400% in the past 3 days. This is a genetic disease and is a reason why I am so bullish on Editas's CRISPR gene editing research.